Posted by Michael Wonder on 31 Aug 2017
Institute for Clinical and Economic Review report finds inadequate evidence to compare PARP inhibitors across key ovarian cancer indications
30 August 2017 - The ICER has released an evidence report assessing the comparative clinical effectiveness and value of three poly (ADP-ribose) polymerase (PARP) inhibitors for treatment of advanced ovarian cancer: olaparib (Lynparza, AstraZeneca), niraparib (Zejula, Tesaro), and rucaparib (Rubraca, Clovis Oncology).
The report reviews evidence on the three drugs for treatment of recurrent, breast cancer gene-mutated ovarian cancer as well as for maintenance therapy in women with recurrent disease who have previously responded to platinum-based chemotherapy (“platinum-sensitive” disease).
This Evidence Report will be the subject of an upcoming public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) in St. Louis, MO on 14 September 2017.
